ETF Holdings Breakdown of ACAD

Stock Name	ACADIA Pharmaceuticals Inc
Ticker	ACAD(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0042251084
LEI	529900O3044NO0PEA039

ACAD institutional holdings

The following institutional investment holdings of ACAD have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 13,172 USD 275,163

2025-10-17 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 151,029 USD 3,154,996

2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 107,717 USD 2,250,208

2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 107,717 USD 2,250,208

2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 82,389 USD 1,721,106 -4.1%

2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 368 USD 7,688 -4.1%

Total = 462,392 USD 9,659,369
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	13,172	USD 275,163
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	151,029	USD 3,154,996
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	107,717	USD 2,250,208
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	107,717	USD 2,250,208
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	82,389	USD 1,721,106 -4.1%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	368	USD 7,688 -4.1%
Total =	462,392	USD 9,659,369

News associated with ACAD

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $28.88: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has […] - 2025-09-12 02:48:53
UBS Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price target increased by investment analysts at UBS Group from $36.00 to $39.00 in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential upside of 63.87% from the […] - 2025-09-11 02:49:04
Deutsche Bank AG Has $12.63 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Deutsche Bank AG trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 760,594 shares of the biopharmaceutical company’s stock after selling 281,853 shares during the period. Deutsche Bank AG owned […] - 2025-08-15 05:17:01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank: Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,256 shares of the biopharmaceutical company’s stock after purchasing an additional 3,389 shares during the period. […] - 2025-08-08 04:56:48
Mackenzie Financial Corp Grows Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Mackenzie Financial Corp boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,379 shares of the biopharmaceutical company’s stock after buying an additional 7,314 shares during the period. Mackenzie […] - 2025-08-06 04:36:58
Envestnet Asset Management Inc. Buys 36,003 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 33.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 142,667 shares of the biopharmaceutical company’s stock after acquiring an additional 36,003 shares during the period. Envestnet Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $2,370,000 […] - 2025-07-29 04:08:59
Cerity Partners LLC Sells 3,872 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 18.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,587 shares of the biopharmaceutical company’s stock after selling 3,872 shares during the period. Cerity Partners LLC’s holdings in ACADIA Pharmaceuticals were […] - 2025-07-28 04:46:48
Xponance Inc. Acquires 1,434 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Xponance Inc. boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,585 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the quarter. Xponance Inc.’s holdings in ACADIA Pharmaceuticals were worth $192,000 as of its […] - 2025-07-21 06:12:11
Bank of New York Mellon Corp Boosts Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of New York Mellon Corp boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 96.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,390 shares of the biopharmaceutical company’s stock after acquiring an additional 394,640 shares during […] - 2025-07-21 04:30:53
New York State Teachers Retirement System Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): New York State Teachers Retirement System grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 547.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,625 shares of the biopharmaceutical company’s stock after acquiring an additional 28,435 shares during […] - 2025-07-11 05:34:49
72,125 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Illinois Municipal Retirement Fund: Illinois Municipal Retirement Fund bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 72,125 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000. Other […] - 2025-07-02 05:28:55
SG Americas Securities LLC Sells 2,465,581 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): SG Americas Securities LLC decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 99.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,150 shares of the biopharmaceutical company’s stock after selling 2,465,581 shares during the quarter. SG Americas […] - 2025-06-27 04:18:48
State of Alaska Department of Revenue Invests $1.13 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): State of Alaska Department of Revenue purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 68,225 shares of the biopharmaceutical company’s stock, valued at approximately $1,133,000. Several other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Principal […] - 2025-06-26 04:43:03
Royal Bank Of Canada Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price raised by stock analysts at Royal Bank Of Canada from $26.00 to $38.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of […] - 2025-06-25 02:36:49
KMDA vs. ACAD: Which Stock Is the Better Value Option?: KMDA vs. ACAD: Which Stock Is the Better Value Option? - 2025-06-18 12:40:06
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells $314,633.88 in Stock: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) Director Laura Brege sold 14,446 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 […] - 2025-06-09 05:36:49
ProShare Advisors LLC Has $763,000 Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): ProShare Advisors LLC increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 28.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,580 shares of the biopharmaceutical company’s stock after purchasing an additional 9,164 shares during the period. ProShare Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $763,000 […] - 2025-05-25 06:03:26
Bank of America Corp DE Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of America Corp DE raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 41.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 680,853 shares of the biopharmaceutical company’s stock after acquiring an additional 199,504 shares during the quarter. Bank of America Corp DE’s holdings in ACADIA Pharmaceuticals were worth […] - 2025-05-23 05:19:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $24.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lifted by Morgan Stanley from $20.00 to $24.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on ACAD. Wall […] - 2025-05-23 02:52:57
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 at Deutsche Bank Aktiengesellschaft: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price objective upped by research analysts at Deutsche Bank Aktiengesellschaft from $20.00 to $35.00 in a research note issued on Wednesday, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […] - 2025-05-23 02:52:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 3.5% Following Analyst Upgrade: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was up 3.5% during mid-day trading on Wednesday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $22.75 and last traded at $22.44. Approximately 376,453 shares traded hands during mid-day trading, a decline of 84% […] - 2025-05-23 02:03:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at StockNews.com: StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […] - 2025-05-22 04:50:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $32.00 Price Target at HC Wainwright: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price increased by equities researchers at HC Wainwright from $27.00 to $32.00 in a research report issued on Monday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 47.53% […] - 2025-05-21 02:42:45
Robert W. Baird Raises ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $31.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […] - 2025-05-20 02:36:58
Northern Trust Corp Has $22.61 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Northern Trust Corp increased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,232,366 shares of the biopharmaceutical company’s stock after buying an additional 106,236 shares during the period. Northern Trust Corp owned 0.74% […] - 2025-05-13 06:14:59
Traders Purchase Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw unusually large options trading activity on Thursday. Stock traders purchased 2,626 call options on the company. This is an increase of 146% compared to the average daily volume of 1,068 call options. Insider Buying and Selling In other news, Director Elizabeth A. Garofalo sold 4,919 shares […] - 2025-05-09 02:38:58
Envestnet Asset Management Inc. Decreases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. lessened its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,664 shares of the biopharmaceutical company’s stock after selling 12,037 shares during the quarter. Envestnet Asset […] - 2025-04-28 04:38:49
Legal & General Group Plc Sells 2,348 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Legal & General Group Plc cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,042 shares of the biopharmaceutical company’s stock after selling 2,348 shares during the quarter. Legal & General […] - 2025-04-25 05:16:54
Cerity Partners LLC Acquires 6,173 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,459 shares of the biopharmaceutical company’s stock after acquiring an additional 6,173 shares during the quarter. […] - 2025-04-24 04:52:50
Summit Investment Advisors Inc. Buys 795 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Summit Investment Advisors Inc. grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 6.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,519 shares of the biopharmaceutical company’s stock after acquiring an additional 795 shares during the period. […] - 2025-04-22 05:07:11

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.